EXEL vs JAZZ: fair value comparison
Exelixis, Inc. and Jazz Pharmaceuticals plc · Updated 2026-10-19
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, JAZZ currently sits closer to the top of our ranking by discount to fair value. EXEL carries the stronger quality grade.
| EXEL | JAZZ | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $62.23 | $210.23 |
| 12-month range | $37.90–$62.83 | $131.16–$261.62 |
| Rank by discount to fair value | #48 of 108 Healthcare | #45 of 108 Healthcare |
| Quality grade | A | B |
| Leverage | Low | Moderate |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Fairly Valued | Undervalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: EXEL fair value analysis · JAZZ fair value analysis